What is the recommended treatment for male breast carcinoma?

Treatment of Male Breast Carcinoma

Men with breast cancer should be treated using the same therapeutic algorithms as women, stratified by hormone receptor (HR) and HER2 status, with surgery followed by adjuvant systemic therapy based on tumor biology and stage. 1, 2

Surgical Management

All men with breast cancer should undergo mastectomy with axillary staging (either sentinel lymph node biopsy or axillary lymph node dissection), as breast-conserving surgery is rarely feasible due to the small volume of male breast tissue. 3, 4

• Sentinel lymph node biopsy is the preferred axillary staging approach for clinically node-negative disease, with completion axillary dissection reserved for positive sentinel nodes. 4
• Post-mastectomy radiation therapy should be offered when tumors are >1 cm and/or when ≥1 axillary lymph node is positive, given the small volume of male breast tissue. 3

Adjuvant Systemic Therapy for Early-Stage Disease

Hormone Receptor-Positive Disease

Tamoxifen 20 mg daily for 5 years is the standard adjuvant endocrine therapy for hormone receptor-positive male breast cancer (strong recommendation). 1, 5

• Men who complete 5 years of tamoxifen, tolerate therapy well, and remain at high risk of recurrence may be offered an additional 5 years of tamoxifen therapy. 1, 5
• If tamoxifen is contraindicated, men may be offered an aromatase inhibitor (AI) combined with a GnRH agonist/antagonist (gonadal suppression is mandatory, as AIs alone are ineffective in men with intact testicular function). 1, 2
• Never use aromatase inhibitors as monotherapy in men, as testosterone from intact testes is aromatized to estrogen, rendering AIs ineffective. 2, 5
• Adjuvant abemaciclib (CDK4/6 inhibitor) for 2 years should be considered in combination with endocrine therapy for high-risk disease (≥4 positive nodes, or 1-3 positive nodes with additional high-risk features such as grade 3 or tumor ≥5 cm). 1

Chemotherapy Indications

Adjuvant chemotherapy should be offered to men with lymph node-positive disease (≥4 nodes) or high-risk node-positive disease (1-3 nodes with adverse features), following the same indications as women. 1, 4, 6

• Anthracycline-based regimens are standard, with taxane addition for higher-risk disease. 6
• Gene expression assays may be considered for men with 1-3 positive nodes to assess prognosis and guide chemotherapy decisions. 1

HER2-Positive Disease

Men with HER2-positive breast cancer should receive adjuvant trastuzumab-based therapy for 1 year, using the same indications and combinations as women. 1

• Pertuzumab may be added to trastuzumab plus chemotherapy for high-risk HER2-positive disease. 1

Bone-Modifying Agents

Men with early-stage breast cancer should NOT be treated with bone-modifying agents to prevent recurrence, but may receive bisphosphonates or denosumab for osteoporosis prevention or treatment. 1, 2

Treatment of Advanced/Metastatic Disease

HR-Positive/HER2-Negative Metastatic Disease

Endocrine therapy is the first-line treatment for HR-positive/HER2-negative metastatic disease, except in cases of visceral crisis or rapidly progressive disease (strong recommendation). 1, 2

First-line endocrine therapy options include:

• Tamoxifen (preferred first-line agent). 2
• Aromatase inhibitor plus GnRH agonist/antagonist (gonadal suppression is mandatory). 1, 2
• Fulvestrant (supported by case series data). 1, 2

CDK4/6 inhibitors should be added to endocrine therapy in men as they are used in women (FDA-approved for men with metastatic HR-positive breast cancer). 1, 2

When metastatic recurrence occurs during adjuvant endocrine therapy, switch to an alternative endocrine agent rather than continuing the same therapy, unless visceral crisis mandates chemotherapy. 1, 2

Sequential endocrine therapy is preferred over immediate chemotherapy in the absence of visceral crisis or rapidly progressive disease. 2

HER2-Positive Metastatic Disease

Men with HER2-positive metastatic breast cancer should receive HER2-targeted therapy (trastuzumab) combined with chemotherapy, using the same indications as women. 1, 2

• HER2-targeted therapy should be continued across multiple lines of treatment. 2

Triple-Negative Metastatic Disease

Chemotherapy is the primary treatment for ER/PR-negative, HER2-negative metastatic disease. 2

• PD-L1 testing should be performed, and PD-L1-positive patients may receive immune checkpoint inhibitor therapy following the same algorithms as women. 1, 2

Targeted Therapies Based on Biomarkers

All men with breast cancer should be offered genetic counseling and germline mutation testing (BRCA2 mutations occur in 10-15% of cases). 2, 7

Targeted therapies should be used based on biomarker status:

• PARP inhibitors for germline BRCA-mutated, HER2-negative disease. 1, 2
• PIK3CA inhibitors for PIK3CA-mutated, HR-positive/HER2-negative disease after progression on endocrine therapy. 1, 2

Biopsy of metastatic lesions should be obtained whenever feasible to confirm histology and reassess ER, PR, and HER2 status, as receptor discordance may occur between primary and metastatic sites. 2

Critical Contraindications and Pitfalls

Testosterone or any androgen supplementation must NEVER be used in men with breast cancer, as testosterone aromatizes to estradiol and can stimulate hormone receptor-positive tumor growth, causing recurrence or progression. 1, 2, 5, 8

Monitor closely for thrombotic events during tamoxifen therapy, as over 80% occur within the first 18 months of treatment. 5

Aromatase inhibitors must always be combined with gonadal suppression in men—monotherapy is ineffective and should never be used. 2, 5, 8

Surveillance

Mammographic surveillance is recommended only for men harboring a breast cancer susceptibility gene (e.g., BRCA2 mutation); routine mammography is not advised for men who have undergone mastectomy. 9

• The risk of breast cancer recurrence continues through 15 years after primary treatment and beyond, requiring long-term clinical surveillance. 5